Zanamivir

證據等級: L5

預測適應症: 2 個

Zanamivir: From Influenza to Pyelonephritis

One-Sentence Summary

Zanamivir is a neuraminidase inhibitor antiviral, originally developed for the treatment and prophylaxis of influenza. The TxGNN model predicts it may be effective for Pyelonephritis, but 0 clinical trials and 0 publications currently support this direction — the prediction currently rests on model association alone, with no biological rationale identified.

Quick Overview

Item	Content
Original Indication	Influenza (based on known antiviral mechanism; not confirmed by Norwegian license text — drug is unmarketed, no license data available)
Predicted New Indication	Pyelonephritis
TxGNN Prediction Score	99.84%
Evidence Level	L5
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data for zanamivir is not available in this evidence pack (original_moa: [Data Gap]). Based on the drug's known pharmacological class, zanamivir is a neuraminidase inhibitor that blocks the influenza viral neuraminidase enzyme, preventing release of new viral particles from infected cells — a mechanism specific to influenza A/B virus replication.

Pyelonephritis is predominantly a bacterial infection of the renal parenchyma (most commonly caused by E. coli and other Enterobacteriaceae). There is no known antibacterial activity, renal-targeting pharmacokinetic property, or immunomodulatory mechanism of zanamivir that would plausibly explain efficacy in this condition. The evidence pack's own repurposing rationale explicitly states that this high TxGNN score reflects a graph-neural-network association only, without supporting biological plausibility, mechanistic literature, or clinical evidence.

A second candidate indication in this evidence pack — "disorder of tyrosine metabolism" (a genetic metabolic disease) — shows the same pattern: the three literature citations retrieved actually concern oseltamivir resistance mutations and neuraminidase inhibition assays (where "tyrosine" appears as a residue name at the H275Y mutation site), not tyrosine metabolic disease. This is a strong indicator of a keyword-matching artifact rather than a genuine biological signal, and reinforces that neither prediction in this pack should be advanced without independent mechanistic or clinical validation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

(Note: literature was retrieved for the second, lower-priority candidate indication — "disorder of tyrosine metabolism" — but on review it concerns oseltamivir/neuraminidase resistance research and is not topically relevant to tyrosine metabolism disorders. It is not presented here as supporting evidence.)

Norway Market Information

Zanamivir is currently not marketed in Norway; no license records are available in this evidence pack.

Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not currently available for this compound.)

Conclusion and Next Steps

Decision: Hold

Rationale: The predicted indication (pyelonephritis) carries an L5 evidence level — model prediction only, with zero clinical trials, zero supportive literature, and no identifiable mechanistic pathway linking a viral neuraminidase inhibitor to a predominantly bacterial renal infection. A second candidate indication in the same pack shows evidence of a literature-retrieval mismatch, further underscoring the need for caution before any further evaluation.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data from DrugBank or primary literature
TFDA/regulatory label warnings and contraindications (currently blocking S1 safety screening per DG001)
Independent mechanistic or preclinical evidence linking neuraminidase inhibition to any renal/urinary tract pathology
Re-validation of the literature retrieval pipeline to rule out keyword-mismatch artifacts (as seen with the tyrosine metabolism candidate)
If no such evidence emerges, this candidate should be deprioritized rather than advanced to further scoring stages
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.